Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Sees Large Decline in Short Interest

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large decline in short interest during the month of May. As of May 31st, there was short interest totalling 24,900 shares, a decline of 59.5% from the May 15th total of 61,500 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 50,800 shares, the short-interest ratio is currently 0.5 days.

Oncotelic Therapeutics Stock Down 12.4%

Shares of OTCMKTS:OTLC opened at $0.05 on Monday. The company has a debt-to-equity ratio of 0.28, a current ratio of 0.01 and a quick ratio of 0.01. The stock has a market cap of $20.17 million, a price-to-earnings ratio of -4.94 and a beta of -0.66. The company has a 50 day moving average of $0.06 and a 200-day moving average of $0.05. Oncotelic Therapeutics has a one year low of $0.02 and a one year high of $0.07.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.